Ulcerative Colitis Pipeline

DelveInsight’s Ulcerative Colitis pipeline report provides a comprehensive insight into the Ulcerative Colitis drug profiles, including clinical and non-clinical stage products. The report also includes Ulcerative Colitis therapeutics assessment by product type, route of administration, and molecule type.

Key Highlights from the Ulcerative Colitis Pipeline Report

• There are currently 110+ drugs in the Ulcerative Colitis pipeline.

• The Ulcerative Colitis pipeline comprises therapies in different clinical stages of development, including Filgotinib, Mirikizumab, Upadacitinib, IMU-838, GLPG3970, RBX 2660, and others.

• Major companies such as Galapagos, Gilead Sciences, Eli Lilly and Company, AbbVie, Immunic, Galapagos, Rebiotix, and others are evaluating their drug candidates to improve the Ulcerative Colitis treatment landscape.

• The US Food and Drug Administration and the European Commission have authorized RINVOQ (Upadacitinib) in 2019 for adult patients with moderately to highly active rheumatoid arthritis who are intolerant of one or more disease-modifying anti-rheumatic medications.

• Some of the other Ulcerative Colitis therapies in the late stages of development include Mirikizumab ( Eli Lilly and Company), IMU-838 (Immunic), GLPG3970 (Galapagos), and others.

• RBX 2660 is being developed and evaluated in Phase I Ulcerative Colitis trials by Rebiotix.

Request for the sample to get an overview of the pipeline landscape @ Ulcerative Colitis Clinical Trial Analysis

Ulcerative Colitis Overview

Ulcerative Colitis (UC) is a long-term condition in which the lining of the colon becomes inflamed, resulting in small open sores or ulcers. These ulcers produce pus and mucus, resulting in abdominal pain. It usually starts in the rectum and progresses upwards. Ulcerative Colitis can strike anyone at any age. The majority of people are diagnosed in their mid-30s. This disease affects both men and women equally, but older men are more likely to be diagnosed than older women.

Ulcerative Colitis Symptoms

The severity of Ulcerative Colitis symptoms varies from person to person. The most common symptom of Ulcerative Colitis is diarrhoea, accompanied by blood in the stool. Diarrhoea is the most common complaint among patients with this disease.

Ulcerative Colitis Treatment

Ulcerative Colitis treatment options include medications, dietary and nutritional changes, and surgical procedures to repair or remove affected portions of the gastrointestinal tract. Combination therapy consisting of oral 5-ASA and rectal 5-ASA or steroids benefits patients with mild to moderate symptoms.

Ulcerative Colitis Pipeline Analysis: Drug Profiles

Upadacitinib: AbbVie

Product Description

Upadacitinib (ABT-494) is a once-daily, oral, selective, and reversible JAK inhibitor beinColitisg studied in various immune-mediated inflammatory diseases. It has a higher inhibitory potency for JAK1 than for JAK2, JAK3, and TYK2. JAK1 inhibits the signaling of numerous important pro-inflammatory cytokines, including interleukin IL-2, IL-6, IL-7, and IL-15, all of which contribute to inflammatory disorders.

Phase III

NCT03653026: In November 2018, AbbVie announced the start of a Phase III, multicenter, randomised, double-blind, placebo-controlled induction study of Upadacitinib (ABT-494) in patients with moderately to severely active ulcerative colitis.

Ulcerative Colitis Pipeline Therapies and Key Companies

• Filgotinib: Galapagos/Gilead Sciences

• Mirikizumab: Eli Lilly and Company

• Upadacitinib: AbbVie

• IMU-838: Immunic

• GLPG3970: Galapagos

• RBX 2660: Rebiotix

Find out more about the emerging therapies @ Ulcerative Colitis Therapies

Ulcerative Colitis Therapeutics Assessment

• By Product Type

• Monotherapy

• Combination Therapy

• By Stage

• Discovery

• Pre-Clinical

• Phase I

• Phase II

• Phase III

• Pre-registration

• By Route of Administration

• Inhalation

• Intravenous

• Oral

• Subcutaneous

• By Molecule Type

• Small Molecule

• Stem Cell Therapy

• Gene Therapy

• Targets

• Immune System

• Multiple Kinase

• By Mechanism of Action

• Protease Inhibitors

• Immunomodulatory

Scope of the Report

Coverage: Global

Ulcerative Colitis Key Players: Galapagos, Gilead Sciences, Eli Lilly and Company, AbbVie, Immunic, Galapagos, Rebiotix, among others

Ulcerative Colitis Pipeline Therapies: Filgotinib, Mirikizumab, Upadacitinib, IMU-838, GLPG3970, RBX 2660, and others

Table of Contents

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Key questions answered in the Ulcerative Colitis Pipeline Report

• What treatment options are available for Ulcerative Colitis?

• How many pharmaceutical companies are working on Ulcerative Colitis treatments?

• Which of these companies’ medications is the most widely used?

• What is the total number of Ulcerative Colitis medications manufactured by each company?

• How many treatments for Ulcerative Colitis are currently being developed in the early, mid, or late stages?

• How many of the medicines that are currently being explored can be used alone or in conjunction with others?

• What are the most critical industry-industry and industry-academic collaboration, mergers and acquisitions, and licensing strategies affecting Ulcerative Colitis?

Related Reports

Ulcerative Proctitis Pipeline Insights

Get a comprehensive analysis of Ulcerative Proctitis pipeline therapies and key companies, including First Wave Bio, Dr Falk Pharma, Alfasigma, Cristcot LLC, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/